Uncovering a Game-Changing Solution for Weight Loss: Oral Semagulatide (GLP-1 receptor agonist, active substance in currently available injectable Ozempic)
.
Novo Nordisk recently announced topline oral semaglutide results. People who received a daily 50-mg dose of oral semaglutide, a glucagon-like peptide-1 receptor agonist, experienced greater #weightloss than those who received a placebo pill, according to results from a 68-week phase 3 clinical trial that included 667 adults with obesity or overweight and 1 or more concurrent conditions. On average, participants experienced a 15.1% decrease in weight after receiving the medication, regardless of treatment adherence, compared with a 2.4% weight loss with the placebo. The amount of weight loss with oral semaglutide was similar to that achieved by people who received a weekly 2.4-mg injected dose of #semaglutide, marketed as Wegovy. Mild or moderate gastrointestinal events were the most common adverse effects
.
Conclusion: In adults with overweight or #obesity without type 2 diabetes, #oralsemaglutide 50 mg once per day led to a superior and clinically meaningful decrease in bodyweight compared with placebo.
["Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial" The Lancet, June 25, 2023]

свернуть